Početna stranica4559 • TYO
add
Zeria Pharmaceutical Co Ltd
Preth. zaklj. cijena
2.244,00 ¥
Dnevni raspon
2.247,00 ¥ - 2.274,00 ¥
Godišnji raspon
1.921,00 ¥ - 2.411,00 ¥
Tržišna kapitalizacija
119,94 mlr. JPY
Prosječna količina
63,62 tis.
P/E omjer
11,86
Prinos dividende
1,99 %
Glavno tržište vrijednosnica
TYO
Vijesti s tržišta
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
(JPY) | ruj 2024.info | Godišnja promjena |
---|---|---|
Prihod | 20,97 mlr. | 14,11 % |
Operativni troškovi | 12,52 mlr. | 14,20 % |
Neto dohodak | 1,85 mlr. | −25,47 % |
Neto profitabilnost | 8,82 | −34,67 % |
Zarada po dionici | — | — |
EBITDA | 4,39 mlr. | 8,29 % |
Efektivna porezna stopa | 17,59 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
(JPY) | ruj 2024.info | Godišnja promjena |
---|---|---|
Gotovinska i kratkoročna ulaganja | 24,36 mlr. | 31,90 % |
Ukupna imovina | 158,34 mlr. | 6,87 % |
Ukupne obveze | 69,77 mlr. | −3,36 % |
Ukupni kapital | 88,57 mlr. | — |
Dionice u optjecaju | 44,08 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 1,12 | — |
Povrat imovine | 4,06 % | — |
Povrat kapitala | 4,89 % | — |
Tok novca
Neto promjena novca
(JPY) | ruj 2024.info | Godišnja promjena |
---|---|---|
Neto dohodak | 1,85 mlr. | −25,47 % |
Gotovina od poslovanja | — | — |
Gotovina iz ulaganja | — | — |
Gotovina iz financiranja | — | — |
Neto promjena novca | — | — |
Slobodan tok novca | — | — |
Više
Zeria Shinyaku Kōgyō KK is a Japanese drug manufacturer that obtained Tillotts Pharma AG.
In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku executive opened a new pharmaceutical company in Tokyo under the name Zeria Yakushō Kenkyusho. In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK.
In 1975, it built a new factory in Kumagaya in Saitama prefecture, before the main factory in Tsukuba which was constructed by Takenaka Corporation in 1988.
In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries,
It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark. The drug itself is developed in Switzerland, Tillotts Parma.
The company owns a 6.63% share of Asuka Seiyaku, also a pharmaceutical company, other than its subsidiaries.
The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ Financial Group, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance as of March 2023. Wikipedia
Glavni izvršni direktor
Osnovano
22. pro 1955.
Web-lokacija
Zaposlenici
1.777